Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) Sees Large Decline in Short Interest

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) saw a significant decline in short interest in the month of June. As of June 30th, there was short interest totaling 6,372 shares, a decline of 35.7% from the June 15th total of 9,904 shares. Based on an average trading volume of 8,436 shares, the short-interest ratio is presently 0.8 days. Approximately 0.1% of the shares of the company are sold short.

Hedge Funds Weigh In On Cryo-Cell International

A hedge fund recently bought a new position in Cryo-Cell International stock. Susquehanna International Group LLP bought a new stake in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned about 0.14% of Cryo-Cell International at the end of the most recent quarter. 10.44% of the stock is currently owned by institutional investors and hedge funds.

Cryo-Cell International Price Performance

Cryo-Cell International stock traded up $0.13 during mid-day trading on Friday, reaching $3.61. 13,284 shares of the stock traded hands, compared to its average volume of 12,321. Cryo-Cell International has a 12-month low of $2.72 and a 12-month high of $5.43. The business’s 50-day moving average is $3.52 and its 200-day moving average is $3.45. The stock has a market capitalization of $29.10 million, a PE ratio of -12.03 and a beta of 0.49.

Cryo-Cell International (NYSEAMERICAN:CCEL) last announced its earnings results on Wednesday, July 15th. The company reported $0.07 earnings per share (EPS) for the quarter. The firm had revenue of $7.78 million during the quarter.

About Cryo-Cell International

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.